Calfactant - Ony
Alternative Names: Infasurf; Infasurf AeroLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Ony
- Developer AbbVie; Ony
- Class Phospholipids; Pulmonary surfactants
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neonatal respiratory distress syndrome
- No development reported Acute lung injury; Bronchitis
- Discontinued Adult respiratory distress syndrome
Most Recent Events
- 27 Jul 2023 ONY in collaboration with Avania plans a phase III (Aero-05) trial for Neonatal respiratory distress syndrome (In infants, In neonates) in the USA in October 2023 (NCT05960929)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Bronchitis(In infants, In neonates) in USA (Inhalation, Aerosol)
- 09 Apr 2021 No development reported - Phase-III for Neonatal respiratory distress syndrome (In neonates) in USA (Inhalation)